On April 21, 2022 Terran Biosciences, Inc. ("Terran"), a biotechnology platform company dedicated to the development of transformational therapies for neurological and psychiatric diseases, reported that has entered into an agreement with Sanofi SA ( " Sanofi") for exclusive worldwide rights to develop and commercialize two late-stage SNC portfolio assets (Press release, Sanofi, APR 21, 2022, View Source;_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc [SID1234612883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These therapies generated four investigational new drug (IND) applications and more than 104 clinical studies involving more than 15,000 subjects in various CNS indications.

Terran plans to rapidly advance the development of these actives for neurological and psychiatric indications, including several novel applications where there is a high unmet medical need. This transaction represents the next key stage in the development of these promising assets.

The deal included an upfront payment, as well as typical milestones and royalties based on success. Specific financial terms of the deal were not disclosed.

"We are grateful to the team at Sanofi for entrusting us with the continued development of these late-stage therapies, which we believe have the potential to transform the paradigm of neuropsychiatry," said Dr. Sam Clark , Founder and CEO of Terran.